The Quest for an Antibody-based HIV Vaccine

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2017 Jan 31

PMID 28133795

Citations 68

Authors

Barton F Haynes

John R Mascola

Affiliations

Soon will be listed here.

Citing Articles

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.

Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S bioRxiv. 2025; .

PMID: 40060701 PMC: 11888476. DOI: 10.1101/2025.03.02.641072.

Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.

Bruton J, Hanke T Vaccines (Basel). 2025; 13(1).

PMID: 39852851 PMC: 11769474. DOI: 10.3390/vaccines13010072.

A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.

Ng T, Furuyama W, Wirchnianski A, Saavedra-Avila N, Johndrow C, Chandran K Front Immunol. 2024; 15:1429909.

PMID: 39081315 PMC: 11286471. DOI: 10.3389/fimmu.2024.1429909.

Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

Nelson G, van Duijn J, Yuki Y, Pau M, Tomaka F, Lavreys L J Virol. 2024; 98(8):e0028124.

PMID: 39046263 PMC: 11338073. DOI: 10.1128/jvi.00281-24.

A branching stochastic evolutionary model of the B-cell repertoire.

Hyrien O, Yanev N J Math Biol. 2024; 89(1):10.

PMID: 38847854 PMC: 11161549. DOI: 10.1007/s00285-024-02102-y.

References

Hoot S, McGuire A, Cohen K, Strong R, Hangartner L, Klein F . Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013; 9(1):e1003106. PMC: 3536657. DOI: 10.1371/journal.ppat.1003106. View

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund N, Gitlin A . Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015; 161(7):1505-15. PMC: 4604566. DOI: 10.1016/j.cell.2015.06.003. View

Kwong P, Chuang G, DeKosky B, Gindin T, Georgiev I, Lemmin T . Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. Immunol Rev. 2017; 275(1):108-128. PMC: 5516196. DOI: 10.1111/imr.12480. View

Ackerman M, Barouch D, Alter G . Systems serology for evaluation of HIV vaccine trials. Immunol Rev. 2017; 275(1):262-270. PMC: 5292205. DOI: 10.1111/imr.12503. View

Sanders R, Moore J . Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev. 2017; 275(1):161-182. PMC: 5299501. DOI: 10.1111/imr.12481. View

Haynes B, Verkoczy L . AIDS/HIV. Host controls of HIV neutralizing antibodies. Science. 2014; 344(6184):588-9. PMC: 4162091. DOI: 10.1126/science.1254990. View

Moore P, Gorman J, Doria-Rose N, Morris L . Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev. 2017; 275(1):217-229. PMC: 5300058. DOI: 10.1111/imr.12501. View

Tomaras G, Plotkin S . Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev. 2017; 275(1):245-261. PMC: 5330182. DOI: 10.1111/imr.12514. View

Kelsoe G, Haynes B . Host controls of HIV broadly neutralizing antibody development. Immunol Rev. 2017; 275(1):79-88. PMC: 5479487. DOI: 10.1111/imr.12508. View

10.

Javaherian K, Langlois A, McDanal C, Ross K, Eckler L, Jellis C . Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989; 86(17):6768-72. PMC: 297927. DOI: 10.1073/pnas.86.17.6768. View

11.

Haynes B, Kelsoe G, Harrison S, Kepler T . B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012; 30(5):423-33. PMC: 3512202. DOI: 10.1038/nbt.2197. View

12.

Doria-Rose N, Schramm C, Gorman J, Moore P, Bhiman J, DeKosky B . Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509(7498):55-62. PMC: 4395007. DOI: 10.1038/nature13036. View

13.

Tian M, Cheng C, Chen X, Duan H, Cheng H, Dao M . Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell. 2016; 166(6):1471-1484.e18. PMC: 5103708. DOI: 10.1016/j.cell.2016.07.029. View

14.

Jardine J, Kulp D, Havenar-Daughton C, Sarkar A, Briney B, Sok D . HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016; 351(6280):1458-63. PMC: 4872700. DOI: 10.1126/science.aad9195. View

15.

Daar E, Li X, Moudgil T, Ho D . High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990; 87(17):6574-8. PMC: 54579. DOI: 10.1073/pnas.87.17.6574. View

16.

Jardine J, Julien J, Menis S, Ota T, Kalyuzhniy O, McGuire A . Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013; 340(6133):711-6. PMC: 3689846. DOI: 10.1126/science.1234150. View

17.

Corey L, B Gilbert P, Tomaras G, Haynes B, Pantaleo G, Fauci A . Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7(310):310rv7. PMC: 4751141. DOI: 10.1126/scitranslmed.aac7732. View

18.

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

19.

Haynes B, Fleming J, St Clair E, Katinger H, Stiegler G, Kunert R . Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005; 308(5730):1906-8. DOI: 10.1126/science.1111781. View

20.

Verkoczy L, Alt F, Tian M . Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev. 2017; 275(1):89-107. PMC: 5300080. DOI: 10.1111/imr.12505. View